COMPARISON OF ALT LEVELS IN TYPE 2 DIABETIC PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE ACCORDING TO THEIR GLYCEMIC CONTROL

Z KHAN; IU KHAN

doi:10.54112/pjicm.v5i01.62

Authors

Z KHAN Department of Medicine Khyber Teaching Hospital Peshawar, Pakistan
IU KHAN Department of Medicine Khyber Teaching Hospital Peshawar, Pakistan

DOI:

https://doi.org/10.54112/pjicm.v5i01.62

Keywords:

Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease, Glycemic Control, Alanine Aminotransferase

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity in patients with type 2 diabetes mellitus (T2DM) and is often associated with elevated alanine aminotransferase (ALT) levels, reflecting hepatic inflammation. Poor glycemic control has been linked to worsening liver pathology, but the relationship between glycemic control and liver enzyme elevation in NAFLD remains to be clarified. Objective: To assess the differences in elevated ALT levels between well-controlled and poorly controlled type 2 diabetic patients with NAFLD. Study Design: Descriptive cross-sectional study. Setting: Department of Medicine at Khyber Teaching Hospital in Peshawar. Duration of Study: The study was conducted over six months from 11 February 2024 to 11 August 2024. Methods: 98 patients aged 30 to 70 years with confirmed T2DM and NAFLD were enrolled and divided into groups based on glycemic control: Group A (well-controlled diabetes) and Group B (poorly controlled diabetes). ALT levels were measured, with values >40 IU/L considered elevated. Data were analyzed using SPSS version 24. Independent t-tests were applied to compare mean ALT levels between the two groups, with a p-value ≤ 0.05 considered statistically significant. Results: The mean age in Group A was 48.94 ± 12.70 years, while Group B was 47.61 ± 12.19 years. Group A had significantly lower mean ALT levels (17.78 ± 11.09 IU/L) compared to Group B (27.43 ± 13.57 IU/L), with the difference being statistically significant (p = 0.0001). Conclusion: Well-controlled type 2 diabetic patients with NAFLD exhibited significantly lower ALT levels compared to those with poorly controlled diabetes. These findings underscore the importance of maintaining optimal glycemic control to mitigate hepatic injury in diabetic patients with NAFLD.

References

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.

Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672-82.

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57.

Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-48.

Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2(3):262-5.

Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793-801.

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389-97.

Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up. Hepatology. 2015;61(5):1547-54.

Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-33.

Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686-90.

Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associatedwith normal ALT values. Hepatology. 2003;37(6):1286-92

Islam S, Rahman S, Haque T, Sumon AH, Ahmed AM, Ali NJE, diabetes, et al. Prevalence of elevated liver enzymes and its association with type 2 diabetes: A cross‐sectional study in Bangladeshi adults. 2020;3(2):e00116.

Malik K, Batool F, Meraj L, Saddiq S, Akbar A, Mughal HH. Comparison of ALT in type 2 diabetics with and without fatty liver disease. J Rawalpindi Med Coll. 2023;27(2):295–298.

Miyake T, Furukawa S, Matsuura B, Yoshida O, Miyazaki M, Shiomi A, et al. Glycemic control is associated with histological findings of nonalcoholic fatty liver disease. Diabetes Metab J. 2024;48(3):440–448.

Akhtar A, Ijaz H, Waseem M, Khan MI, Saif Y, Iqbal H, Batool SA, et al. The interplay between diabetes and non-alcoholic fatty liver disease: a cross-sectional study from Pakistan. Ann Med Surg. 2024;86(4):1929–1932.

Kinoshita T, Shimoda M, Nakashima K, Fushimi Y, Hirata Y, Tanabe A, et al. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. J Diabetes Investig. 2020;11(6):1612–1622.

Mahran HN, Saber LM, Alghaithy AA Elareefy AA. The role of elevated alanine aminotransferase (ALT), FasL and atherogenic dyslipidemia in type II diabetes mellitus. J Taibah University Med Sci. 2016;12(1):8–13.